Stocktoria
DAXOR CORP (DXR) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.81% (safety: safe). FY2011 revenue was $1.4M at a -496.8% net margin.
Beneish M-score: -2.36 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.378 |
| Retained earnings / assets | 0.289 |
| EBIT / assets | -0.067 |
| Equity / liabilities | 0.732 |
About DAXOR CORP
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
FAQ
Is DXR financially healthy?
DAXOR CORP's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DXR pay a dividend, and is it safe?
Yes. DAXOR CORP pays a dividend yielding about 1.81% with a -14.7% payout ratio, rated “safe” for safety.
How profitable is DXR?
In FY2011, DAXOR CORP had a net margin of -496.8% and a return on equity of -19.8%.
What is the analyst price target for DXR?
The average Wall-Street price target for DAXOR CORP is $22.50, about 120.6% above the recent price, from 2 analysts.
Is DXR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DAXOR CORP: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone, a dividend yield of 1.81%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2011-12-31. Facts plus Stocktoria's own computed scores — not investment advice.